TY - JOUR
T1 - Combination chemotherapy with fluorouracil, adriamycin, cis-Platinum and VM-26 in advanced transitional cell carcinoma of the urinary tract
AU - Veronesi, A.
AU - Galligioni, E.
AU - Lo Re, G.
AU - Sorio, R.
AU - Saracchini, S.
AU - Francini, M.
AU - Merlo, A.
AU - Dal Bo, V.
AU - Monfardini, S.
PY - 1986
Y1 - 1986
N2 - From October 1981 to October 1984, 42 consecutive patients with locally advanced unresectable or metastatic transitional cell carcinoma of the urinary tract were treated with cis-Platinum 50 mg/m2 i.v. and Adriamycin 50 mg/m2 i.v. day 1, and Fluorouracil 500mg/m2 i.v. and VM26 100 mg/m2 days 1 and 8, every 3 weeks. In the 36 evaluable patients, 4 complete remissions and 15 partial remissions were noted (52.7% response rate). Of the 12 patients with previously untreated, locally advanced bladder carcinoma, 8 responded, with 3 pathologically confirmed complete remissions. Toxicity was moderate. Median survival was 44 weeks. This 4-drug combination had significant palliative activity in our patient population. Its role in the preoperative setting deserves further evaluation.
AB - From October 1981 to October 1984, 42 consecutive patients with locally advanced unresectable or metastatic transitional cell carcinoma of the urinary tract were treated with cis-Platinum 50 mg/m2 i.v. and Adriamycin 50 mg/m2 i.v. day 1, and Fluorouracil 500mg/m2 i.v. and VM26 100 mg/m2 days 1 and 8, every 3 weeks. In the 36 evaluable patients, 4 complete remissions and 15 partial remissions were noted (52.7% response rate). Of the 12 patients with previously untreated, locally advanced bladder carcinoma, 8 responded, with 3 pathologically confirmed complete remissions. Toxicity was moderate. Median survival was 44 weeks. This 4-drug combination had significant palliative activity in our patient population. Its role in the preoperative setting deserves further evaluation.
UR - http://www.scopus.com/inward/record.url?scp=0022862219&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0022862219&partnerID=8YFLogxK
U2 - 10.1016/0277-5379(86)90079-9
DO - 10.1016/0277-5379(86)90079-9
M3 - Article
C2 - 3595670
AN - SCOPUS:0022862219
SN - 0959-8049
VL - 22
SP - 1457
EP - 1460
JO - European Journal of Cancer
JF - European Journal of Cancer
IS - 12
ER -